What question did this study set out to answer?

The aim is to evaluate the effectiveness of tildrakizumab on disease severity and patient-reported outcomes in moderate-to-severe chronic plaque psoriasis.

April 26, 2026Dermatology and Therapy0 citationsOpen Access

Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study

PFPaola Facheris FPFrancesco Piscazzi GFGiovanni Fiorillo

Key Points

The aim is to evaluate the effectiveness of tildrakizumab on disease severity and patient-reported outcomes in moderate-to-severe chronic plaque psoriasis.
Prospective real-world study design
Assessment of disease severity using PASI
Evaluation of patient-reported outcomes (PROMs)
At week 16, tildrakizumab significantly improved PASI scores, indicating lower disease severity.
PROM improvements correlate strongly with PASI initially but diminish over time, suggesting adaptation.
Integration of PROMs into long-term management is recommended to fully capture patient-centered benefits.

Abstract

Tildrakizumab improves both objective disease severity and quality of life at week 16. PASI strongly correlates with PROM improvements early in treatment, but correlations diminish over time, suggesting possible adaptation once skin clearance is sustained. PROMs should be integrated into long-term management to capture patient-centered benefits beyond skin clearance.

AI에게 질문

Bookmark

View Full Paper